Resources

In addition to outlining five ways to optimize your message strategy and drive sales, this playbook also includes real messages and payer reactions in breast cancer.

Learn the causes of rebate leakage and how MMIT’s Contract Validation solution can provide a workflow automation platform that enables manufacturers to validate formulary positioning at scale.

In addition to outlining five ways to optimize your message strategy and drive sales, this playbook also includes real messages and payer reactions in migraine.

In addition to outlining five ways to optimize your message strategy and drive sales, this playbook also includes real messages and payer reactions in rheumatoid arthritis.

In addition to outlining five ways to optimize your message strategy and drive sales, this playbook also includes real messages and payer reactions in oncology biosimilars.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

In addition to outlining five ways to optimize your message strategy and drive sales, this playbook also includes real messages and payer reactions in atopic dermatitis.

In addition to outlining five ways to optimize your message strategy and drive sales, this playbook also includes real messages and payer reactions in non-small cell lung cancer.

Why aren’t pharma teams shifting market access strategies to earlier phases of drug development? The influence of payers and PBMs is often poorly understood.

As specialty pharmaceuticals consume an ever-larger share of healthcare benefit dollars, payers, providers and other healthcare organizations are realizing the importance of managing drugs administered under the medical benefit, which most often are specialty drugs.

Learn how a data-driven market access strategy and competitor benchmarking led to launch excellence.

Learn how MMIT and MarketLauncher helped a medtech company engage a difficult-to-reach health plan audience.

Learn how a healthcare services company partnered with MMIT to help support its provider network with coverage data.

Learn how a pharma company preparing for a drug launch partnered with MMIT to gain insight into the most effective messaging with payers.

Learn how a pharma company leveraged MMIT’s Strategic Launch Report combined with In-Depth Interviews to get a unique view into the market access path for its therapy.

Learn how a pharma company partnered with MMIT’ to understand payer perceptions of its brand over time as competitors enter the market.

Learn how a small pharma company leveraged MMIT’s Analytics platform to drive its messaging with healthcare providers as it launched its first commercial product at the start of the COVID-19 pandemic.

Take a look into how a PBM was able to gain a deeper understanding of their market potential and obtain competitive intelligence with Payer Landscape.

Take a look into how a specialty pharmacy partnered with MMIT to enhance its referral process and decrease time to therapy for patients.

Learn how a medical device company partnered with and leveraged MMIT’s Payer Landscape data.

Learn how a pharma company’s market access team leveraged MMIT’s quantitative online surveys to obtain a custom pricing and contracting study to support its drug launch.

Learn how a pharma company leveraged MMIT’s advisory board service to get unique insights from payers and physician key opinion leaders (KOLs) to support its drug launch.

Learn how a healthcare IT organization automated payer account identification and outreach.

Learn how a healthcare IT organization was able to gain a deeper understanding of their market potential and obtain competitive intelligence with Payer Landscape.

Learn how a product’s placement on pathways affects its utilization and uptake, and ultimately, patient’s access to life saving therapies.

Explore how we can expect the market to react and how factors such as launch timing, interchangeability, and contracting will shape the immunology landscape.

Access barriers to the use of innovative technology such as administrative burden and reimbursement challenges. We will also touch upon payer concern about costs which might be underlying these issues.

Learn when and how to select the right analogs to set the most accurate expectations and payer strategy at launch.

Learn how claims reimbursement is currently being managed, as well as some best practices for leveraging specialty drug data to streamline the process.

Learn how formularies are currently managed, examine some of the key challenges faced by payers and PBMs, and evaluate new integrated solutions to optimize management of both pharmacy and medically covered drugs.

Payer coverage policies continue to become more complex with increasing access hurdles. Dig into ways to sift through the noise and uncover payer account intervention and pull-through opportunities via dashboards and real-time alerts.

Understanding a large complex payer and their subsidiaries to segment your contracting plan or recognizing lives enrollment shifts in specific geographies, having payer data source solution to support your sales and marketing team is crucial.

MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).

MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.

MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.

MMIT recently conducted a syndicated simulated P&T Heart Failure session focused on the entry Farxiga, and anticipated entry of Jardiance, into heart failure.

Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.

MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia.

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

RJ Health, an MMIT company, conducted a survey on NDC mandates. In 2016 and 2021, we asked payers questions such as how they are managing NDCs and who performs unit conversions. We compiled these results

Learn how Patient Access Analytics from MMIT and Panalgo can show how coverage decisions influence physician prescriber behavior.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

Inform site selection, drive trial awareness and enrollment, and uncover patient-centric signals for evidence generation and outcomes studies.

Learn more about MMIT’s Bridging as a Service solution.

Learn more about MMIT’s Surveillance solution.

PULSE Pathways includes data on third parties that develop pathways for IDNs and payers.

PULSE Provider includes clinical pathway information for IDNs that create and maintain their own pathways.

Read a summary of the Patient Access Analytics solution from MMIT and Panalgo.

Learn more about MMIT’s proactive, economic, precise, and comprehensive solution that can help manufacturers promote their therapies to specific providers using lab test results before a diagnosis and/or prescribing decision is made.

Learn more about MMIT’s FormTrak integration with Veeva CRM.

Contract Validation is a workflow automation platform that enables manufacturers to validate formulary positioning at scale by crosschecking the contract language against MMIT’s industry-leading data.

Learn more about MMIT’s Formulary Navigator solution.

Learn how RJ Health helped a niche healthcare company bolster its payer communications.

Without the right tools, your account managers will face many obstacles trying to win more pharma business. We’ll give you our top tips on how to engage with pharma manufacturers and differentiate your organization.

MMIT’s new FormTrak integration in Veeva CRM changes how pharma companies detail healthcare providers. Now your field teams can access FormTrak seamlessly within Veeva thanks to the first native market access integration.

Access dozens of payer profiles and in-depth narratives, focused on top health plans, PBMs and all 50 U.S. states.

Access dozens of payer profiles and in-depth narratives, focused on top health plans, PBMs and all 50 U.S. states.

Access dozens of payer profiles and in-depth narratives, focused on top health plans, PBMs and all 50 U.S. states.

You need a variety of resources to develop a successful payer strategy. Download our infographic to learn how MMIT can help your organization.

P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).

P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).

P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).

P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).

P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.

P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.

P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.

P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.

P&T Session Atopic Dermatitis: MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.

P&T Session Atopic Dermatitis: MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.

P&T Session Atopic Dermatitis: MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.

P&T Session Atopic Dermatitis: MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.

P&T Session Atopic Dermatitis: MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.

P&T Session Heart Failure:  MMIT recently conducted a syndicated simulated P&T Heart Failure session focused on the entry Farxiga, and anticipated entry of Jardiance, into heart failure.

P&T Session Heart Failure:  MMIT recently conducted a syndicated simulated P&T Heart Failure session focused on the entry Farxiga, and anticipated entry of Jardiance, into heart failure.

P&T Session Heart Failure:  MMIT recently conducted a syndicated simulated P&T Heart Failure session focused on the entry Farxiga, and anticipated entry of Jardiance, into heart failure.

P&T Session Heart Failure:  MMIT recently conducted a syndicated simulated P&T Heart Failure session focused on the entry Farxiga, and anticipated entry of Jardiance, into heart failure.

P&T Session NSCLC: Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.

P&T Session NSCLC: Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.

P&T Session NSCLC: Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.

P&T Session NSCLC: Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.

MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia.

MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia.

MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia.

MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia.

View a demo of the Payer Landscape tool.

Understanding and maintaining insight into payer enrollment is difficult. At MMIT, we are focused on helping our clients understand the complex payer landscape.

Learn more about how MMIT’s FormTrak solution can help your team.

Learn more about how MMIT’s FormTrak solution can help your team.

Learn more about how MMIT’s FormTrak solution can help your team.

How Medical Billing and Coding Can Impact Patient Access. Hear from the experts from RJ Health, an MMIT company.

Factors complicate the payer enrollment landscape, making it challenging to project membership rolls across payers, geographies and channels. See enrollment projections, the drivers behind them and what you can expect from the 2021 payer landscape.

MMIT’s FormTrak tool helps prescribers get their patients on the right therapy even amid complex drug coverage requirements. FormTrak’s integration in Veeva CRM, pharma field teams can deliver an access message right in Veeva’s platform.